Document is current
Any future updates will be listed below
-
Authors
Bolton, Kelly L.
Ptashkin, Ryan N.
Gao, Teng
Braunstein, Lior
Devlin, Sean M.
Kelly, Daniel
Patel, Minal
Berthon, Antonin
Syed, Aijazuddin
Yabe, Mariko
Coombs, Catherine C.
Caltabellotta, Nicole M.
Walsh, Mike
Offit, Kenneth
Stadler, Zsofia
Mandelker, Diana
Schulman, Jessica
Patel, Akshar
Philip, John https://orcid.org/0000-0002-0535-7178
Bernard, Elsa https://orcid.org/0000-0002-2057-7187
Gundem, Gunes
Ossa, Juan E. Arango
Levine, Max https://orcid.org/0000-0001-5156-9086
Martinez, Juan S. Medina
Farnoud, Noushin
Glodzik, Dominik
Li, Sonya
Robson, Mark E. https://orcid.org/0000-0002-3109-1692
Lee, Choonsik
Pharoah, Paul D. P. https://orcid.org/0000-0001-8494-732X
Stopsack, Konrad H. https://orcid.org/0000-0002-0722-1311
Spitzer, Barbara
Mantha, Simon
Fagin, James https://orcid.org/0000-0002-2365-2517
Boucai, Laura https://orcid.org/0000-0002-8852-1120
Gibson, Christopher J.
Ebert, Benjamin L. https://orcid.org/0000-0003-0197-5451
Young, Andrew L.
Druley, Todd
Takahashi, Koichi https://orcid.org/0000-0002-8027-9659
Gillis, Nancy
Ball, Markus
Padron, Eric
Hyman, David M.
Baselga, Jose
Norton, Larry
Gardos, Stuart
Klimek, Virginia M.
Scher, Howard
Bajorin, Dean
Paraiso, Eder
Benayed, Ryma
Arcila, Maria E.
Ladanyi, Marc
Solit, David B. https://orcid.org/0000-0002-6614-802X
Berger, Michael F.
Tallman, Martin
Garcia-Closas, Montserrat https://orcid.org/0000-0003-1033-2650
Chatterjee, Nilanjan
Diaz, Luis A. Jr https://orcid.org/0000-0002-7079-8914
Levine, Ross L. https://orcid.org/0000-0002-7884-1905
Morton, Lindsay M.
Zehir, Ahmet https://orcid.org/0000-0001-5406-4104
Papaemmanuil, Elli https://orcid.org/0000-0003-1709-8983
-
Funding
Funding for this research was provided by:
European Hematology Association
Gabrielle’s Angel Foundation for Cancer Research
V Foundation for Cancer Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08 CA241318)
American Society of Hematology
Edward P. Evans Foundation
Starr Cancer Consortium
U.S. Department of Health & Human Services | National Institutes of Health (P50 CA172012, K12 CA120780, P50 CA172012, P50 CA172012, UG1 HL069315)
Conquer Cancer Foundation
U.S. Department of Defense (W81XWH-18-1-0330)
Cycle for Survival
EIF | Stand Up To Cancer (SU2C-AACR-DT22-17)
- License Information
-
More Information
Article History
Received: 5 April 2020
Accepted: 2 September 2020
First Online: 26 October 2020
Competing interests
: The authors declare the following competing interests: K.L.B. has received research funding from GRAIL. C.C.C. has received honoraria from AbbVie, Loxo, H3 Biomedicine, Medscape, Octapharma and Pharmacyclics; has served as a consultant for AbbVie, Covance, Cowen & Co. and Dedham Group; and has received institutional research funding from AROG, Gilead, Loxo, H3 Biomedicine and Incyte. Z.S. has an immediate family member who holds consulting/advisory roles within the field of ophthalmology with Allergan, Adverum Biotechnologies, Alimera Sciences, Biomarin, Fortress Biotech, Genentech, Novartis, Optos, Regeneron, Regenxbio and Spark Therapeutics. E.B. receives research funding from Celgene. D.G. is a consultant of MNM Diagnostics and has received honoraria for speaking and scientific advisory engagements with Celgene, Prime Oncology, Novartis, Illumina and Kyowa Hakko Kirin. S.L. is an employee of GRAIL. M.E.R. holds an uncompensated advisory role with AstraZeneca, Daiichi-Sankyo, Merck and Pfizer and receives institutional research funding from AstraZeneca, AbbVie, Medivation and Pfizer. B.L.E. has received research funding from Celgene and Deerfield. T.D. is the Chief Medical Officer, ArcherDX, Inc. and receives salary from and holds an ownership stake in the company. K.T. receives consultancy fees from Symbio Pharmaceuticals. D.M.H. has consulted for Fount, Chugai, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer and Genentech/Roche; has equity in Fount; and has received research grants from Loxo, Bayer, Puma and AstraZeneca. J.B. is an employee of AstraZeneca; is on the Board of Directors of Foghorn and is a past board member of Varian Medical Systems, Bristol‐Myers Squibb, Grail, Aura Biosciences and Infinity Pharmaceuticals; has performed consulting and/or advisory work for Grail, PMV Pharma, ApoGen, Juno, Eli Lilly, Seragon, Novartis and Northern Biologics; has stock or other ownership interests in PMV Pharma, Grail, Juno, Varian, Foghorn, Aura, Infinity Pharmaceuticals, ApoGen and Northern Biologics, as well as Tango and Venthera, for which he is a co‐founder; and has previously received honoraria or travel expenses from Roche, Novartis and Eli Lilly. M. Ladanyi serves on the advisory boards for AstraZeneca, Bristol Myers Squibb, Takeda, Bayer and Merck, and has received research support from Loxo Oncology and Helsinn Therapeutics. D.B.S. has served as a consultant for or received honoraria from Pfizer, Loxo Oncology, Lilly Oncology, Illumina and Vivideon Therapeutics. M.F.B. is on the advisory board for Roche and receives research support from Illumina. M.S.T. receives research funding from AbbVie, Cellerant, Orsenix, ADC Therapeutics and Biosight; serves on the advisory boards of Daiichi-Sankyo, KAHR, Rigel, Nohla, Delta Fly Pharma, Tetraphase, Oncolyze and Jazz Pharma; has received royalties from UpToDate; and has received research funding from Incyte, Kura Oncology and Celgene. L.A.D. is a member of the board of directors of Personal Genome Diagnostics (PGDx) and Jounce Therapeutics; is a paid consultant to PGDx and Neophore; is an uncompensated consultant for Merck (with the exception of travel and research support for clinical trials); is an inventor of multiple licensed patents related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy from Johns Hopkins University, some of which are associated with equity or royalty payments directly to Johns Hopkins and L.A.D.; and holds equity in PGDx, Jounce Therapeutics, Thrive Earlier Detection and Neophore; his wife holds equity in Amgen. The terms of all of these arrangements are being managed by Johns Hopkins and Memorial Sloan Kettering in accordance with their conflict of interest policies. R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Loxo, Imago, C4 Therapeutics and Isoplexis, which include equity interest; receives research support from and has consulted for Celgene and Roche and has consulted for Lilly, Janssen, Astellas, Morphosys and Novartis; and has received honoraria from Roche, Lilly and Amgen for invited lectures and from Gilead for grant reviews. A.Z. received honoraria from Illumina. E. Papaemmanuil receives research funding from Celgene and is a cofounder in Isabl Technologies, a software analytics company for high-throughput clinical whole-genome and RNA-sequencing analyses. The remaining authors declare no competing interests.
